CRISPR Therapeutics CEO Samarth Kulkarni recently sold 6,967 shares for $366,324.86, adding to previous sales in January totaling roughly $5.53 million in CRSP stock, reducing his stake by 2.99%. This comes after the company reported a significant earnings and revenue miss, though institutional ownership is high and analyst ratings average a “Hold” with a $64.24 price target. The company specializes in gene-editing therapies for serious diseases, with its lead program CTX001 for sickle cell disease.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock
CRISPR Therapeutics CEO Samarth Kulkarni recently sold 6,967 shares for $366,324.86, adding to previous sales in January totaling roughly $5.53 million in CRSP stock, reducing his stake by 2.99%. This comes after the company reported a significant earnings and revenue miss, though institutional ownership is high and analyst ratings average a “Hold” with a $64.24 price target. The company specializes in gene-editing therapies for serious diseases, with its lead program CTX001 for sickle cell disease.